Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is facing a setback as their proof-of-concept study for SGT-210 in Darier disease did not show differentiation from vehicle on efficacy assessments. The company has decided to discontinue development in this indication, but will continue to explore potential future applications for SGT-210 through small, targeted clinical studies. Although the discontinuation of SGT-210 does not impact our price objective, we maintain our Buy rating and 12-month price target of $50 per share as the company continues to have a strong pipeline and potential for growth with their SGT-610 product for the treatment of skin diseases like Basal Cell Carcinoma in Gorlin syndrome patients.

Sol-Gel Technologies is expected to face challenges in generating significant revenue from its product candidate SGT-610 as it targets a small market of approximately 11K patients in the U.S. Furthermore, the pivotal top-line data for SGT-610 is not expected to be released until late 2026, with potential FDA approval not occurring until late 2027 at the earliest. This timeline, along with the relatively modest projected peak revenue of $300M annually, makes it unlikely for Sol-Gel to see significant financial success from SGT-610, leading to a negative outlook for the company's stock.